Leukemia: A Review of Data from the ASH 2021 Meeting - Episode 1

ASH 2021: Novel Therapy in Acute Lymphocytic Leukemia

Published on: 
, ,

Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.

Data from the following clinical trials are discussed:

  • 1233: Updated results from a phase I study of hyper-CVAD with sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia
  • 1231: Superior overall survival with blinatumomab versus chemotherapy as pre-transplant consolidation treatment in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL): longer follow-up (FU) of a phase 3 randomized controlled trial (RCT)
  • 4028: Successful outpatient administration of blinatumomab infusion in pediatric patients with acute lymphoblastic leukemia
  • 516: Isatuximab in combination with chemotherapy in pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia (ISAKIDS): interim analysis
  • 428: Real-world outcomes for pediatric and young adult patients with relapsed refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Supported in part by Takeda Oncology. Content developed independently by Onclive®.